The effect of magnesium supplementation on vascular calcification in chronic kidney disease - A randomised clinical trial (MAGiCAL-CKD): Essential study design and rationale

BMJ Open

Volumn 7, Issue 6, 2017, Pages

  Bressendorff, Iain ^a   Hansen, Ditte ^b   Schou, Morten ^b   Kragelund, Charlotte ^b   Brandi, Lisbet ^a  

^a HILLERØD HOSPITAL   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

chronic kidney disease; Magnesium; mineral metabolism; randomised clinical trial; vascular calcification

Indexed keywords

MAGNESIUM HYDROXIDE; PLACEBO; MAGNESIUM;

ARTICLE; BONE DENSITY; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CORONARY ARTERY CALCIFICATION; CORONARY ARTERY CALCIUM SCORE; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ESTIMATED GLOMERULAR FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MINERAL METABOLISM; MULTICENTER STUDY; OBSERVATIONAL STUDY; PATIENT SAFETY; PROSPECTIVE STUDY; PULSE WAVE; QTC INTERVAL; RANDOMIZED CONTROLLED TRIAL; STUDY DESIGN; SUPPLEMENTATION; ADOLESCENT; ADULT; AGED; BLOOD VESSEL CALCIFICATION; CLINICAL TRIAL; COMPLICATION; CORONARY ARTERY DISEASE; DENMARK; DIAGNOSTIC IMAGING; DISEASE EXACERBATION; FEMALE; GLOMERULUS FILTRATION RATE; MALE; METHODOLOGY; MIDDLE AGED; NORWAY; STATISTICAL MODEL; X-RAY COMPUTED TOMOGRAPHY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BONE DENSITY; CORONARY ARTERY DISEASE; DENMARK; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; LINEAR MODELS; LOGISTIC MODELS; MAGNESIUM; MALE; MIDDLE AGED; NORWAY; PULSE WAVE ANALYSIS; RENAL INSUFFICIENCY, CHRONIC; RESEARCH DESIGN; TOMOGRAPHY, X-RAY COMPUTED; VASCULAR CALCIFICATION; YOUNG ADULT;

EID: 85021280372     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2017-016795     Document Type: Article

References (41)

1. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-47.
2. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305.
3. Budoff MJ, Rader DJ, Reilly MP, et al. Relationship of estimated GFR and coronary artery calcification in the CRIC (Chronic renal insufficiency cohort) Study. Am J Kidney Dis 2011;58:519-26.
4. Chirinos JA, Khan A, Bansal N, et al. Arterial stiffness, central pressures, and incident hospitalized heart failure in the chronic renal insufficiency cohort study. Circ Heart Fail 2014;7:709-16.
5. Bansal N, McCulloch CE, Lin F, et al. Different components of blood pressure are associated with increased risk of atherosclerotic cardiovascular disease versus heart failure in advanced chronic kidney disease. Kidney Int 2016;90:1348-56.
6. Matsushita K, Sang Y, Ballew SH, et al. Subclinical atherosclerosis measures for cardiovascular prediction in CKD. J Am Soc Nephrol 2015;26:439-47.
7. Yamada S, Giachelli CM. Vascular calcification in CKD-MBD: Roles for phosphate, FGF23, and Klotho. Bone 2016. Epub ahead of print: pii: S8756-3282(16)30345-3.
8. Montezano AC, Zimmerman D, Yusuf H, et al. Vascular smooth muscle cell differentiation to an osteogenic phenotype involves TRPM7 modulation by magnesium. Hypertension 2010;56:453-62.
9. Kircelli F, Peter ME, Sevinc Ok E, et al. Magnesium reduces calcification in bovine vascular smooth muscle cells in a dosedependent manner. Nephrol Dial Transplant 2012;27:514-21.
10. Louvet L, Büchel J, Steppan S, et al. Magnesium prevents phosphate-induced calcification in human aortic vascular smooth muscle cells. Nephrol Dial Transplant 2013;28:869-78.
11. Montes de Oca A, Guerrero F, Martinez-Moreno JM, et al. Magnesium inhibits wnt/-catenin activity and reverses the osteogenic transformation of vascular smooth muscle cells. PLoS One 2014;9:e89525.
12. Xu J, Bai Y, Jin J, et al. Magnesium modulates the expression levels of calcification-associated factors to inhibit calcification in a timedependent manner. Exp Ther Med 2015;9:1028-34.
13. Zelt JG, McCabe KM, Svajger B, et al. Magnesium modifies the impact of calcitriol treatment on vascular calcification in experimental chronic kidney disease. J Pharmacol Exp Ther 2015;355:451-62.
14. Sonou T, Ohya M, Yashiro M, et al. Magnesium prevents phosphateinduced vascular calcification via TRPM7 and Pit-1 in an aortic tissue culture model. Hypertens Res 2017. Epub ahead of print: 26 Jan 2017.
15. Alesutan I, Tuffaha R, Auer T, et al. Inhibition of osteo/chondrogenic transformation of vascular smooth muscle cells by MgCl2 via calcium-sensing receptor. J Hypertens 2017;35:523-32.
16. Kanbay M, Yilmaz MI, Apetrii M, et al. Relationship between serum magnesium levels and cardiovascular events in chronic kidney disease patients. Am J Nephrol 2012;36:228-37.
17. Sakaguchi Y, Fujii N, Shoji T, et al. Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis. Kidney Int 2014;85:174-81.
18. Sakaguchi Y, Fujii N, Shoji T, et al. Magnesium modifies the cardiovascular mortality risk associated with hyperphosphatemia in patients undergoing hemodialysis: a cohort study. PLoS One 2014;9:e116273.
19. Ishimura E, Okuno S, Yamakawa T, et al. Serum magnesium concentration is a significant predictor of mortality in maintenance hemodialysis patients. Magnes Res 2007;20:237-44.
20. João Matias P, Azevedo A, Laranjinha I, et al. Lower serum magnesium is associated with cardiovascular risk factors and mortality in haemodialysis patients. Blood Purif 2014;38(3-4):244-52.
21. Fein P, Weiss S, Ramos F, et al. Serum magnesium concentration is a significant predictor of mortality in peritoneal Dialysis patients. Adv Perit Dial 2014;30:90-3.
22. de Roij van Zuijdewijn CL, Grooteman MP, Bots ML, et al. Serum magnesium and sudden death in European Hemodialysis Patients. PLoS One 2015;10:e0143104.
23. Lacson E, Wang W, Ma L, et al. Serum magnesium and mortality in Hemodialysis Patients in the United States: a Cohort Study. Am J Kidney Dis 2015;66:1056-66.
24. Kurita N, Akizawa T, Fukagawa M, et al. Contribution of dysregulated serum magnesium to mortality in hemodialysis patients with secondary hyperparathyroidism: a 3-year cohort study. Clin Kidney J 2015;8:744-52.
25. Tin A, Grams ME, Maruthur NM, et al. Results from the Atherosclerosis risk in communities study suggest that low serum magnesium is associated with incident kidney disease. Kidney Int 2015;87:820-7.
26. Van Laecke S, Nagler EV, Verbeke F, et al. Hypomagnesemia and the risk of death and GFR decline in chronic kidney disease. Am J Med 2013;126:825-31.
27. Sakaguchi Y, Iwatani H, Hamano T, et al. Magnesium modifies the association between serum phosphate and the risk of progression to end-stage kidney disease in patients with non-diabetic chronic kidney disease. Kidney Int 2015;88:833-42.
28. Sakaguchi Y, Hamano T, Nakano C, et al. Association between Density of coronary artery calcification and serum magnesium levels among patients with chronic kidney disease. PLoS One 2016;11:e0163673.
29. Turgut F, Kanbay M, Metin MR, et al. Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis. Int Urol Nephrol 2008;40:1075-82.
30. Mortazavi M, Moeinzadeh F, Saadatnia M, et al. Effect of magnesium supplementation on carotid intima-media thickness and flowmediated dilatation among hemodialysis patients: a double-blind, randomized, placebo-controlled trial. Eur Neurol 2013;69:309-16.
31. Agatston AS, Janowitz WR, Hildner FJ, et al. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990;15:827-32.
32. Pasch A, Farese S, Gräber S, et al. Nanoparticle-based test measures overall propensity for calcification in serum. J Am Soc Nephrol 2012;23:1744-52.
33. Russo D, Corrao S, Miranda I, et al. Progression of coronary artery calcification in predialysis patients. Am J Nephrol 2007;27:152-8.
34. Russo D, Miranda I, Ruocco C, et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 2007;72:1255-61.
35. Bressendorff I, Hansen D, Schou M, et al. Oral magnesium supplementation in chronic kidney disease stages 3 and 4: efficacy, Safety, and effect on serum calcification Propensity-A Prospective Randomized Double-Blinded Placebo-Controlled Clinical Trial. Kidney Int Rep 2017;2:380-9.
36. Smith ER, Ford ML, Tomlinson LA, et al. Serum calcification propensity predicts all-cause mortality in predialysis CKD. J Am Soc Nephrol 2014;25:339-48.
37. Bøhmer T, Røseth A, Holm H, et al. Bioavailability of oral magnesium supplementation in female students evaluated from elimination of magnesium in 24-hour urine. Magnes Trace Elem 1990;9:272-8.
38. Walker AF, Marakis G, Christie S, et al. Mg citrate found more bioavailable than other Mg preparations in a randomised, doubleblind study. Magnes Res 2003;16:183-91.
39. de Francisco AL, Leidig M, Covic AC, et al. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant 2010;25:3707-17.
40. Block GA, Wheeler DC, Persky MS, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 2012;23:1407-15.
41. Seifert ME, de las Fuentes L, Rothstein M, et al. Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease. Am J Nephrol 2013;38:158-67.